BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250714
DTEND;VALUE=DATE:20250717
DTSTAMP:20260515T065832
CREATED:20250214T115327Z
LAST-MODIFIED:20250214T115819Z
UID:40483-1752451200-1752710399@www.pharmajournalist.com
SUMMARY:3rd Obesity & Weight Loss Summit
DESCRIPTION:The 3rd Obesity & Weight Loss Summit has been announced and is set to ignite the field.  The summit will unite experts to harness novel targets and GLP combination therapies to improve efficacy\, tolerability\, and longer lasting clinical outcomes. \n \nJoin us at this unique\, industry-led summit to: \n\nDiscover groundbreaking combination therapies and novel targets to minimize and manage side effects to improve patient tolerability with Boehringer Ingelheim and Altimmune\nExplore innovative approaches for preserving muscle mass whilst still achieving significant weight loss to prevent sarcopenia with Regeneron and iBio\nInvestigate cutting-edge advancements in drug delivery technologies\, including long-acting formulations and novel administration routes for simpler patient use with Biolexis and Syntis Bio\nLearn strategies to drive long-term weight management success by personalizing treatment for more prolonged patient continuation and satisfaction with Prive Bio and Fractyl Therapeutic\n\nHear from the titans of the pharmaceutical industry – Eli Lilly\, Novo Nordisk\, AstraZeneca\, Altimmune\, High Tide Therapeutics\, RenBio\, and many more – as they share their groundbreaking research and strategies for developing more effective\, tolerable\, and long-lasting weight management solutions. \nObesity rates are increasing\, and the pressure is on for real change. Don’t miss this pivotal opportunity to network with 70+ obesity scientists and drug development experts forge collaborations\, and be part of the solution. The future of weight loss treatment is being written now – be there! \nFor more information\, view the full Event Guide here: https://ter.li/rish42
URL:http://www.pharmajournalist.com/event/3rd-obesity-weight-loss-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250715
DTEND;VALUE=DATE:20250718
DTSTAMP:20260515T065832
CREATED:20250409T111422Z
LAST-MODIFIED:20250411T115959Z
UID:40893-1752537600-1752796799@www.pharmajournalist.com
SUMMARY:5th Inner Ear Disorders Therapeutics Summit
DESCRIPTION:Building on recent breakthroughs in gene therapy\, 2025 is poised for major advancements in cell transplants\, gamma secretase inhibitors\, anti-inflammatory programs\, and more to address the growing unmet need for more transformative hearing loss treatments. \n \nWith an aging population and an urgent need to restore a greater spectrum of hearing abilities beyond the scope of current device-based interventions\, there has never been a more critical time for the field to unite and drive progress. \nCoined by industry as the only meeting of its kind\, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical\, translational\, and clinical bottlenecks\, the 5th Inner Ear Disorders Therapeutics Summit returns as your definitive forum to benchmark learnings from past failures and ignite renewed optimism into the hearing loss therapeutic landscape. \nWith pioneering insights from Regeneron\, Biogen\, Acousia\, Rinri\, Ting Therapeutics\, Lineage Cell Therapeutics\, Gateway and more\, join 50+ of your peers to: \n\nAdvance translatable models to recapitulate complex human inner ear pathophysiology\nDeepen knowledge of molecular and genetic pathways underlying age-related\, noise-induced\, and congenital hearing loss to uncover druggable pathways\nEvaluate clinical progress in gene therapy for restored hearing and decipher the journey to success in Phase III populations\nOvercome translational challenges of bringing advanced therapies\, including small molecule and cell-based approaches\, to the clinic\nUncover opportunities for drug-device combinations to enable precise drug delivery and enhance the hearing preservation capabilities of cochlear implants\nHear large pharma and investor perspectives on what must be demonstrated to de-risk business opportunities within the hearing disorders space\n\nJoin this unparalleled forum of biotech innovators\, pharma stakeholders\, medical device manufacturers\, and leading academics in a collaborative atmosphere to advance otoprotection\, hearing restoration\, and gene therapy R&D and transform the treatment of hearing loss. \nFind out more in our brochure: https://ter.li/22rawz
URL:http://www.pharmajournalist.com/event/5th-inner-ear-disorders-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR